FX.co ★ Avadel Pharma's SNDA For Lumryz Gets FDA Approval

Avadel Pharmaceuticals plc (AVDL), a prominent name in the biopharmaceutical industry, has proudly announced that the U.S. Food and Drug Administration (FDA) has granted approval for its supplemental new drug application for LUMRYZ. This medication is intended for the treatment of cataplexy or excessive daytime sleepiness (EDS) in narcolepsy patients aged 7 and older.

Greg Divis, CEO of Avadel Pharmaceuticals, stated, "This approval signifies a significant achievement for the narcolepsy community, especially for younger patients and their caregivers who often face challenges associated with waking during the night for treatment. With the expanded labeling, pediatric patients, aged 7 and above, afflicted by narcolepsy now have access to the same once-nightly treatment option available to adults, which eliminates the need for a middle-of-the-night dose, thereby uninterruptedly maintaining their sleep."

Narcolepsy is a chronic neurological disorder that hampers the brain's capability to regulate the sleep-wake cycle. It affects approximately 1 in 2,000 individuals in the United States, with about 5% of those patients being younger than 18 years.

LUMRYZ, an extended-release sodium oxybate formulated for once-at-bedtime administration, received its initial FDA approval on May 1, 2023, specifically for treating cataplexy or EDS in adult patients with narcolepsy.